CAD 0.05
(11.11%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 625.14 Thousand CAD | -28.24% |
2022 | 871.12 Thousand CAD | 149.13% |
2021 | 349.67 Thousand CAD | 158.34% |
2020 | 135.35 Thousand CAD | 62.87% |
2019 | 83.1 Thousand CAD | 76.4% |
2018 | 47.11 Thousand CAD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 874.69 Thousand CAD | 39.92% |
2024 Q2 | 1.06 Million CAD | 21.45% |
2023 Q2 | 344.19 Thousand CAD | -43.92% |
2023 Q3 | 472.21 Thousand CAD | 37.19% |
2023 Q1 | 613.74 Thousand CAD | -29.55% |
2023 FY | 625.14 Thousand CAD | -28.24% |
2023 Q4 | 625.14 Thousand CAD | 32.39% |
2022 Q4 | 871.12 Thousand CAD | 40.5% |
2022 FY | 871.12 Thousand CAD | 149.13% |
2022 Q2 | 666.17 Thousand CAD | 21.87% |
2022 Q1 | 546.64 Thousand CAD | 56.33% |
2022 Q3 | 620.03 Thousand CAD | -6.93% |
2021 Q3 | 103.17 Thousand CAD | -24.38% |
2021 Q2 | 136.43 Thousand CAD | 95.72% |
2021 FY | 349.67 Thousand CAD | 158.34% |
2021 Q1 | 69.7 Thousand CAD | -48.5% |
2021 Q4 | 349.67 Thousand CAD | 238.91% |
2020 Q1 | 44.83 Thousand CAD | -46.05% |
2020 Q3 | 91.23 Thousand CAD | -8.34% |
2020 Q4 | 135.35 Thousand CAD | 48.36% |
2020 Q2 | 99.53 Thousand CAD | 122.0% |
2020 FY | 135.35 Thousand CAD | 62.87% |
2019 Q2 | 47.99 Thousand CAD | 0.0% |
2019 FY | 83.1 Thousand CAD | 76.4% |
2019 Q3 | 29.59 Thousand CAD | -38.33% |
2019 Q1 | - CAD | -100.0% |
2019 Q4 | 83.1 Thousand CAD | 180.79% |
2018 Q4 | 47.11 Thousand CAD | 0.0% |
2018 FY | 47.11 Thousand CAD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aquarius Surgical Technologies Inc. | 5.17 Million CAD | 87.932% |
Cannabix Technologies Inc. | 248.02 Thousand CAD | -152.052% |